Side Effects of olaparib: A Synthesis of Findings from 12 Studies

  1. Home
  2. Side Effects of olaparib
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of olaparib: A Synthesis of Findings from 12 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of olaparib: A Synthesis of Findings from 12 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Olaparib is a PARP inhibitor that has shown promising results in treating certain types of cancer. 3 found that olaparib, in combination with oligo-fucoidan, can effectively prevent metastasis and recurrence of triple-negative breast cancer in mice. 9 reported a case study of a woman with recurrent ovarian cancer who was successfully treated with olaparib for 50 months without experiencing any recurrence. The study 5 suggested that promoter methylation of DNA homologous recombination genes could be a predictor of olaparib's effectiveness in testicular germ cell tumors. 10 found that patients with lower body weight are more likely to experience nausea when taking olaparib.

Reasons for Side Effects

Side effects of olaparib are attributed to its PARP inhibitory action and other pharmacological effects. 6 suggests that PARP inhibitors have multiple pharmacological targets, leading to a range of side effects.

Common Side Effects

Nausea

Nausea is a common side effect of olaparib. The study 10 found that underweight patients are more prone to nausea during olaparib treatment. 4 explored the use of pyridoxine (vitamin B6) as a successful treatment and preventative measure for nausea and vomiting caused by PARP inhibitors.

Anemia

Anemia is another potential side effect of olaparib, as reported in 9 .

Skin Side Effects

11 reported a case of dermatosis on the left dorsal hand as a rare side effect of olaparib.

Countermeasures for Side Effects

Nausea

To manage nausea caused by olaparib, antiemetics and dietary modifications can be helpful. The study 1 compared the effectiveness of ramosetron and ondansetron in preventing gastrointestinal side effects from cisplatin-containing chemotherapy.

Anemia

Treatment for anemia includes iron supplements and hematopoietic growth factors.

Skin Side Effects

Topical medications such as steroid ointments can be effective for skin side effects.

Comparison Between Studies

Common Points of Studies

Several studies confirm that olaparib is an effective cancer treatment. It is also generally considered a safe medication.

Differences Between Studies

The efficacy and side effects of olaparib vary across studies, due to factors such as cancer type, patient condition, and treatment methods.

Points to Note for Application in Real Life

Olaparib is a crucial medication in cancer treatment. However, it is essential to take it as directed by your doctor, being aware of its potential side effects. Early detection and proper management of side effects are vital when using olaparib.

Limitations of Current Research

The research on olaparib is still in its early stages, and there are many unknowns regarding its long-term effects and side effects.

Future Research Directions

Further research is needed to gain a better understanding of the long-term effects and side effects of olaparib, as well as its effectiveness in treating various cancers. The development of new therapies to minimize olaparib side effects is also crucial.

Conclusion

Olaparib is a promising cancer treatment, but it can have side effects. When taking olaparib, it's vital to follow your doctor's instructions and be aware of potential side effects.

Literature analysis of 12 papers
Positive Content
11
Neutral Content
1
Negative Content
0
Article Type
1
0
0
1
10
1.

Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study.

Author: ShiYuankai, HeXiaohui, YangSheng, AiBin, ZhangChanggong, HuangDingzhi, DongMei, LiuPeng, ZhouShengyu, HanXiaohong

Effective
Safe

Ramosetron is a long-lasting and safe antiemetic agent.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Olaparib dose re-escalation in ovarian cancer patients who experienced severe and/or uncommon adverse events: A case series.

Author: NguSiew-Fei, TseKa-Yu, ChuMandy M Y, NganHextan Y S, ChanKaren K L

Olaparib treatment for ovarian cancer
Adverse events

This case series studied the adverse events (AEs) of olaparib, a poly(adenosine diphosphate-ribose) polymerase inhibitor, in Chinese patients with ovarian cancer. The study aimed to develop strategies for managing AEs and adjusting doses in real-world settings.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Pyridoxine for prevention and treatment of PARP inhibitor induced nausea and vomiting.

Author: OstbyStuart A, SmithHaller J, LeathCharles A

Nausea treatment
PARPi emetogenicity

This report presents three cases of olaparib-related nausea and vomiting successfully mitigated by pyridoxine (vitamin B6). Pyridoxine was effective both as a therapeutic and prophylactic option for managing significant treatment-related nausea and vomiting with poly-ADP ribose polymerase inhibitor (PARPi) use.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

5.

Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors.

Author: LoboJoão, ConstâncioVera, Guimarães-TeixeiraCatarina, Leite-SilvaPedro, Miranda-GonçalvesVera, SequeiraJosé Pedro, PistoniLaura, GuimarãesRita, CantanteMariana, BragaIsaac, MaurícioJoaquina, LooijengaLeendert H J, HenriqueRui, JerónimoCarmen

TGCT treatment

This study investigated the potential of using promoter methylation of homologous recombination (HR) genes as a predictor of response to poly-ADP ribose polymerase inhibitors (PARPis) in testicular germ cell tumors (TGCTs). The study identified specific HR genes that could be predictive of PARPi response and showed that TGCT cell lines with different methylation levels exhibited varying sensitivity to Olaparib, a PARPi.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale.

Author: SandhuDaranjit, AntolinAlbert A, CoxAnthony R, JonesAlan M

Anemia
Diarrhea
Fatigue
Hepatotoxicity
Hypertension
Hypothyroidism
Myelosuppression
Nausea
Neutropenia
Thrombocytopenia
Vomiting

The polypharmacology of PARP inhibitors, despite their similar mode of action, influences their adverse drug reaction (ADR) profile. This suggests that the choice of PARP inhibitor should consider the specific ADR profile of each drug.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital.

Author: MendesDiogo, RigueiroGraça, SilvaRui S, PenedonesAna, AlvesCarlos, SousaGabriela, Batel-MarquesFrancisco

Cancer drug safety
Gastrointestinal disorders
Hematologic disorders

This intensive safety monitoring program was feasible and allowed identifying serious and unexpected adverse drug reactions in cancer patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

9.

Long-Term Follow-Up of a Female Patient Treated with Olaparib-Hope for a Long Life without Relapse?

Author: KozłowskiMateusz, NowakKatarzyna, Cymbaluk-PłoskaAneta

Cancer remission
Effective treatment
Anemia

This clinical case presents the treatment of a 56-year-old female with a mutation in the BRCA1 gene with recurrent epithelial ovarian cancer using olaparib.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

10.

[Elucidation of Influential Factors on Nausea Associated with Olaparib Administration].

Author: NakagomiSanae, NakazawaYusuke, KageyamaAkira, HaradaDai, SuzukiJiro, NagasakiEijiro, KawakuboTakashi

Olaparib
Hematotoxicity
Nausea

This study investigated the factors influencing nausea in patients receiving olaparib treatment. Lower body weight was found to be associated with increased risk of nausea, suggesting that dose per body weight might be a contributing factor.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : Japanese

11.

Olaparib-induced cutaneous side effects in a patient with recurrent ovarian cancer.

Author: GouRei, HorikawaNaoki, KosakaKenzo

BRCA mutation treatment
Ovarian cancer treatment
Dermatosis
Quality of life impact

PARP inhibitors are a new class of drugs used to treat ovarian cancer, especially in patients with BRCA gene mutations. This study reports a rare side effect of olaparib, a PARP inhibitor, which caused a skin rash on the hand.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.